Personalized Medicine for Cancer - from Inventions to Innovation

Purpose and goal

The aim of this agenda is to develop a triple-helix approach, leading to innovative products and processes, better use of drugs, health economy benefits, improved survival figures for patients, and instituting Sweden as a continuous leading force in the development of Personalized Medicine in cancer.

Results and expected effects

The progress of successfully implementing PM into Swedish health care will generate a new market for e.g. diagnostics, since the use of biomarkers will be a prerequisite for correct stratification of patients for treatment decisions. The waiting times for initiation of both treatment and clinical studies will be shorter, new companies will be formed and will generate more tax revenue and employment opportunities. In addition, the implementationen of PM aim to improve patients Progression Free Survival, increase the number of clinical studies based on PM and patients included.

Approach and implementation

This Agenda aims to facilitate national collaboration between the industry, academia and health care providers. The health care system needs to have a confident and long-term relationship to both the medical industry and the university based research. For example, national coordination of clinical trials and collaborative based access to patient cohorts with a coordinated utilization of patient registers is mandatory. We aim to facilitate such collaborations, being a prerequisite for increased access to cutting edge research for improved clinical efficacy